一种旨在检测微小差异的更精确的HIV整合检测方法发现，接受高效抗逆转录病毒治疗（HAART）的患者体内整合DNA水平较低。
A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients.
作者信息
Yu Jianqing J, Wu Te Lang, Liszewski Megan K, Dai Jihong, Swiggard William J, Baytop Clifford, Frank Ian, Levine Bruce L, Yang Wei, Theodosopoulos Theodore, O'Doherty Una
机构信息
Department of Pathology and Laboratory Medicine, Division of Transfusion Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
出版信息
Virology. 2008 Sep 15;379(1):78-86. doi: 10.1016/j.virol.2008.05.030. Epub 2008 Jul 22.
Many studies report the level of total viral DNA in HIV-infected patients, but few studies report the level of integrated DNA. It is important to measure integrated DNA in HIV-infected patients because the information could shed light on the effectiveness of antiretroviral therapy, especially intensified therapy, when viral loads may remain undetectable. In order to develop an integration assay for patient samples, we enhanced the sensitivity of our prior integration assay. To do this, we exploited a technique that we developed, called repetitive sampling, and optimized reaction conditions for rare event detection, rather than large dynamic range. We also designed our primers to match more conserved regions of HIV. The result is a new, sensitive, quantitative assay that allows us to measure integrated DNA in HIV-infected patients. When we applied our integration assay to patient PBMCs, we found that the use of HAART is associated with reduced levels of integrated DNA.
许多研究报告了HIV感染患者体内的总病毒DNA水平，但很少有研究报告整合DNA的水平。在HIV感染患者中测量整合DNA很重要，因为这些信息可以揭示抗逆转录病毒疗法，尤其是强化疗法的有效性，此时病毒载量可能仍无法检测到。为了开发针对患者样本的整合检测方法，我们提高了之前整合检测方法的灵敏度。为此，我们利用了一种我们开发的技术，称为重复采样，并针对罕见事件检测而非大动态范围优化了反应条件。我们还设计了引物以匹配HIV更保守的区域。结果是一种新的、灵敏的定量检测方法，使我们能够测量HIV感染患者体内的整合DNA。当我们将整合检测方法应用于患者外周血单核细胞（PBMCs）时，我们发现使用高效抗逆转录病毒疗法（HAART）与整合DNA水平降低有关。
Zotero 插件